1 Multiple Myeloma Drugs Market Overview 1.1 Product Overview and Scope of Multiple Myeloma Drugs 1.2 Multiple Myeloma Drugs Segment by Type 1.2.1 Global Multiple Myeloma Drugs Sales Growth Rate Comparison by Type (2021-2027) 1.2.2 Chemotherapy 1.2.3 Corticosteroids 1.2.4 Immunomodulators 1.2.5 Monoclonal Antibodies 1.2.6 Histone Deacetylase (HDAC) Inhibitors 1.2.7 Proteasome Inhibitors 1.2.8 Others 1.3 Multiple Myeloma Drugs Segment by Application 1.3.1 Global Multiple Myeloma Drugs Sales Comparison by Application: (2021-2027) 1.3.2 Men 1.3.3 Women 1.4 Global Multiple Myeloma Drugs Market Size Estimates and Forecasts 1.4.1 Global Multiple Myeloma Drugs Revenue 2016-2027 1.4.2 Global Multiple Myeloma Drugs Sales 2016-2027 1.4.3 Multiple Myeloma Drugs Market Size by Region: 2016 Versus 2021 Versus 2027 2 Multiple Myeloma Drugs Market Competition by Manufacturers 2.1 Global Multiple Myeloma Drugs Sales Market Share by Manufacturers (2016-2021) 2.2 Global Multiple Myeloma Drugs Revenue Market Share by Manufacturers (2016-2021) 2.3 Global Multiple Myeloma Drugs Average Price by Manufacturers (2016-2021) 2.4 Manufacturers Multiple Myeloma Drugs Manufacturing Sites, Area Served, Product Type 2.5 Multiple Myeloma Drugs Market Competitive Situation and Trends 2.5.1 Multiple Myeloma Drugs Market Concentration Rate 2.5.2 The Global Top 5 and Top 10 Largest Multiple Myeloma Drugs Players Market Share by Revenue 2.5.3 Global Multiple Myeloma Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans 3 Multiple Myeloma Drugs Retrospective Market Scenario by Region 3.1 Global Multiple Myeloma Drugs Retrospective Market Scenario in Sales by Region: 2016-2021 3.2 Global Multiple Myeloma Drugs Retrospective Market Scenario in Revenue by Region: 2016-2021 3.3 North America Multiple Myeloma Drugs Market Facts & Figures by Country 3.3.1 North America Multiple Myeloma Drugs Sales by Country 3.3.2 North America Multiple Myeloma Drugs Revenue by Country 3.3.3 U.S. 3.3.4 Canada 3.4 Europe Multiple Myeloma Drugs Market Facts & Figures by Country 3.4.1 Europe Multiple Myeloma Drugs Sales by Country 3.4.2 Europe Multiple Myeloma Drugs Revenue by Country 3.4.3 Germany 3.4.4 France 3.4.5 U.K. 3.4.6 Italy 3.4.7 Russia 3.5 Asia Pacific Multiple Myeloma Drugs Market Facts & Figures by Region 3.5.1 Asia Pacific Multiple Myeloma Drugs Sales by Region 3.5.2 Asia Pacific Multiple Myeloma Drugs Revenue by Region 3.5.3 China 3.5.4 Japan 3.5.5 South Korea 3.5.6 India 3.5.7 Australia 3.5.8 Taiwan 3.5.9 Indonesia 3.5.10 Thailand 3.5.11 Malaysia 3.5.12 Philippines 3.5.13 Vietnam 3.6 Latin America Multiple Myeloma Drugs Market Facts & Figures by Country 3.6.1 Latin America Multiple Myeloma Drugs Sales by Country 3.6.2 Latin America Multiple Myeloma Drugs Revenue by Country 3.6.3 Mexico 3.6.4 Brazil 3.6.5 Argentina 3.7 Middle East and Africa Multiple Myeloma Drugs Market Facts & Figures by Country 3.7.1 Middle East and Africa Multiple Myeloma Drugs Sales by Country 3.7.2 Middle East and Africa Multiple Myeloma Drugs Revenue by Country 3.7.3 Turkey 3.7.4 Saudi Arabia 3.7.5 U.A.E 4 Global Multiple Myeloma Drugs Historic Market Analysis by Type 4.1 Global Multiple Myeloma Drugs Sales Market Share by Type (2016-2021) 4.2 Global Multiple Myeloma Drugs Revenue Market Share by Type (2016-2021) 4.3 Global Multiple Myeloma Drugs Price by Type (2016-2021) 5 Global Multiple Myeloma Drugs Historic Market Analysis by Application 5.1 Global Multiple Myeloma Drugs Sales Market Share by Application (2016-2021) 5.2 Global Multiple Myeloma Drugs Revenue Market Share by Application (2016-2021) 5.3 Global Multiple Myeloma Drugs Price by Application (2016-2021) 6 Key Companies Profiled 6.1 Amgen 6.1.1 Amgen Corporation Information 6.1.2 Amgen Description and Business Overview 6.1.3 Amgen Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2016-2021) 6.1.4 Amgen Multiple Myeloma Drugs Product Portfolio 6.1.5 Amgen Recent Developments/Updates 6.2 Johnson & Johnson 6.2.1 Johnson & Johnson Corporation Information 6.2.2 Johnson & Johnson Description and Business Overview 6.2.3 Johnson & Johnson Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2016-2021) 6.2.4 Johnson & Johnson Multiple Myeloma Drugs Product Portfolio 6.2.5 Johnson & Johnson Recent Developments/Updates 6.3 Celgene 6.3.1 Celgene Corporation Information 6.3.2 Celgene Description and Business Overview 6.3.3 Celgene Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2016-2021) 6.3.4 Celgene Multiple Myeloma Drugs Product Portfolio 6.3.5 Celgene Recent Developments/Updates 6.4 Takeda Pharmaceutical 6.4.1 Takeda Pharmaceutical Corporation Information 6.4.2 Takeda Pharmaceutical Description and Business Overview 6.4.3 Takeda Pharmaceutical Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2016-2021) 6.4.4 Takeda Pharmaceutical Multiple Myeloma Drugs Product Portfolio 6.4.5 Takeda Pharmaceutical Recent Developments/Updates 6.5 Novartis 6.5.1 Novartis Corporation Information 6.5.2 Novartis Description and Business Overview 6.5.3 Novartis Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2016-2021) 6.5.4 Novartis Multiple Myeloma Drugs Product Portfolio 6.5.5 Novartis Recent Developments/Updates 6.6 Daiichi Sankyo 6.6.1 Daiichi Sankyo Corporation Information 6.6.2 Daiichi Sankyo Description and Business Overview 6.6.3 Daiichi Sankyo Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2016-2021) 6.6.4 Daiichi Sankyo Multiple Myeloma Drugs Product Portfolio 6.6.5 Daiichi Sankyo Recent Developments/Updates 6.7 Merck 6.6.1 Merck Corporation Information 6.6.2 Merck Description and Business Overview 6.6.3 Merck Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2016-2021) 6.4.4 Merck Multiple Myeloma Drugs Product Portfolio 6.7.5 Merck Recent Developments/Updates 6.8 AB Science 6.8.1 AB Science Corporation Information 6.8.2 AB Science Description and Business Overview 6.8.3 AB Science Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2016-2021) 6.8.4 AB Science Multiple Myeloma Drugs Product Portfolio 6.8.5 AB Science Recent Developments/Updates 6.9 Teva 6.9.1 Teva Corporation Information 6.9.2 Teva Description and Business Overview 6.9.3 Teva Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2016-2021) 6.9.4 Teva Multiple Myeloma Drugs Product Portfolio 6.9.5 Teva Recent Developments/Updates 6.10 PharmaMar 6.10.1 PharmaMar Corporation Information 6.10.2 PharmaMar Description and Business Overview 6.10.3 PharmaMar Multiple Myeloma Drugs Sales, Revenue and Gross Margin (2016-2021) 6.10.4 PharmaMar Multiple Myeloma Drugs Product Portfolio 6.10.5 PharmaMar Recent Developments/Updates 7 Multiple Myeloma Drugs Manufacturing Cost Analysis 7.1 Multiple Myeloma Drugs Key Raw Materials Analysis 7.1.1 Key Raw Materials 7.1.2 Key Suppliers of Raw Materials 7.2 Proportion of Manufacturing Cost Structure 7.3 Manufacturing Process Analysis of Multiple Myeloma Drugs 7.4 Multiple Myeloma Drugs Industrial Chain Analysis 8 Marketing Channel, Distributors and Customers 8.1 Marketing Channel 8.2 Multiple Myeloma Drugs Distributors List 8.3 Multiple Myeloma Drugs Customers 9 Multiple Myeloma Drugs Market Dynamics 9.1 Multiple Myeloma Drugs Industry Trends 9.2 Multiple Myeloma Drugs Growth Drivers 9.3 Multiple Myeloma Drugs Market Challenges 9.4 Multiple Myeloma Drugs Market Restraints 10 Global Market Forecast 10.1 Multiple Myeloma Drugs Market Estimates and Projections by Type 10.1.1 Global Forecasted Sales of Multiple Myeloma Drugs by Type (2022-2027) 10.1.2 Global Forecasted Revenue of Multiple Myeloma Drugs by Type (2022-2027) 10.2 Multiple Myeloma Drugs Market Estimates and Projections by Application 10.2.1 Global Forecasted Sales of Multiple Myeloma Drugs by Application (2022-2027) 10.2.2 Global Forecasted Revenue of Multiple Myeloma Drugs by Application (2022-2027) 10.3 Multiple Myeloma Drugs Market Estimates and Projections by Region 10.3.1 Global Forecasted Sales of Multiple Myeloma Drugs by Region (2022-2027) 10.3.2 Global Forecasted Revenue of Multiple Myeloma Drugs by Region (2022-2027) 11 Research Finding and Conclusion 12 Methodology and Data Source 12.1 Methodology/Research Approach 12.1.1 Research Programs/Design 12.1.2 Market Size Estimation 12.1.3 Market Breakdown and Data Triangulation 12.2 Data Source 12.2.1 Secondary Sources 12.2.2 Primary Sources 12.3 Author List 12.4 Disclaimer

List of Tables Table 1. Global Multiple Myeloma Drugs Sales (K Units) Growth Rate Comparison by Type (2021-2027) Table 2. Global Multiple Myeloma Drugs Sales (K Units) Comparison by Application (2021-2027) Table 3. Global Multiple Myeloma Drugs Market Size by Region (US$ Million) (2016 VS 2021 VS 2027) Table 4. Key Manufacturers Multiple Myeloma Drugs Covered in This Study Table 5. Global Multiple Myeloma Drugs Sales (K Units) of Key Manufacturers (2016-2021) Table 6. Global Multiple Myeloma Drugs Sales Market Share by Manufacturers (2016-2021) Table 7. Global Multiple Myeloma Drugs Revenue (US$ Million) by Manufacturers (2016-2021) Table 8. Global Multiple Myeloma Drugs Revenue Share by Manufacturers (2016-2021) Table 9. Global Market Multiple Myeloma Drugs Average Price (USD/Unit) of Key Manufacturers (2016-2021) Table 10. Manufacturers Multiple Myeloma Drugs Manufacturing Sites and Area Served Table 11. Manufacturers Multiple Myeloma Drugs Product Type Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 13. Global Multiple Myeloma Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Multiple Myeloma Drugs as of 2020) Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans Table 15. Global Multiple Myeloma Drugs Sales by Region (2016-2021) & (K Units) Table 16. Global Multiple Myeloma Drugs Sales Market Share by Region (2016-2021) Table 17. Global Multiple Myeloma Drugs Revenue by Region (2016-2021) & (US$ Million) Table 18. North America Multiple Myeloma Drugs Sales by Country (2016-2021) & (K Units) Table 19. North America Multiple Myeloma Drugs Sales Market Share by Country (2016-2021) Table 20. North America Multiple Myeloma Drugs Revenue by Country (2016-2021) & (US$ Million) Table 21. North America Multiple Myeloma Drugs Revenue Market Share by Country (2016-2021) Table 22. Europe Multiple Myeloma Drugs Sales by Country (2016-2021) & (K Units) Table 23. Europe Multiple Myeloma Drugs Sales Market Share by Country (2016-2021) Table 24. Europe Multiple Myeloma Drugs Revenue by Country (2016-2021) & (US$ Million) Table 25. Europe Multiple Myeloma Drugs Revenue Market Share by Country (2016-2021) Table 26. Asia Pacific Multiple Myeloma Drugs Sales by Region (2016-2021) & (K Units) Table 27. Asia Pacific Multiple Myeloma Drugs Sales Market Share by Region (2016-2021) Table 28. Asia Pacific Multiple Myeloma Drugs Revenue by Region (2016-2021) & (US$ Million) Table 29. Asia Pacific Multiple Myeloma Drugs Revenue Market Share by Region (2016-2021) Table 30. Latin America Multiple Myeloma Drugs Sales by Country (2016-2021) & (K Units) Table 31. Latin America Multiple Myeloma Drugs Sales Market Share by Country (2016-2021) Table 32. Latin America Multiple Myeloma Drugs Revenue by Country (2016-2021) & (US$ Million) Table 33. Latin America Multiple Myeloma Drugs Revenue Market Share by Country (2016-2021) Table 34. Middle East and Africa Multiple Myeloma Drugs Sales by Country (2016-2021) & (K Units) Table 35. Middle East and Africa Multiple Myeloma Drugs Sales Market Share by Country (2016-2021) Table 36. Middle East and Africa Multiple Myeloma Drugs Revenue by Country (2016-2021) & (US$ Million) Table 37. Middle East and Africa Multiple Myeloma Drugs Revenue Market Share by Country (2016-2021) Table 38. Global Multiple Myeloma Drugs Sales (K Units) by Type (2016-2021) Table 39. Global Multiple Myeloma Drugs Sales Market Share by Type (2016-2021) Table 40. Global Multiple Myeloma Drugs Revenue (Million US$) by Type (2016-2021) Table 41. Global Multiple Myeloma Drugs Revenue Share by Type (2016-2021) Table 42. Global Multiple Myeloma Drugs Price (USD/Unit) by Type (2016-2021) Table 43. Global Multiple Myeloma Drugs Sales (K Units) by Application (2016-2021) Table 44. Global Multiple Myeloma Drugs Sales Market Share by Application (2016-2021) Table 45. Global Multiple Myeloma Drugs Revenue (Million US$) by Application (2016-2021) Table 46. Global Multiple Myeloma Drugs Revenue Share by Application (2016-2021) Table 47. Global Multiple Myeloma Drugs Price (USD/Unit) by Application (2016-2021) Table 48. Amgen Corporation Information Table 49. Amgen Description and Business Overview Table 50. Amgen Multiple Myeloma Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 51. Amgen Multiple Myeloma Drugs Product Table 52. Amgen Recent Developments/Updates Table 53. Johnson & Johnson Corporation Information Table 54. Johnson & Johnson Description and Business Overview Table 55. Johnson & Johnson Multiple Myeloma Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 56. Johnson & Johnson Multiple Myeloma Drugs Product Table 57. Johnson & Johnson Recent Developments/Updates Table 58. Celgene Corporation Information Table 59. Celgene Description and Business Overview Table 60. Celgene Multiple Myeloma Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 61. Celgene Multiple Myeloma Drugs Product Table 62. Celgene Recent Developments/Updates Table 63. Takeda Pharmaceutical Corporation Information Table 64. Takeda Pharmaceutical Description and Business Overview Table 65. Takeda Pharmaceutical Multiple Myeloma Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 66. Takeda Pharmaceutical Multiple Myeloma Drugs Product Table 67. Takeda Pharmaceutical Recent Developments/Updates Table 68. Novartis Corporation Information Table 69. Novartis Description and Business Overview Table 70. Novartis Multiple Myeloma Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 71. Novartis Multiple Myeloma Drugs Product Table 72. Novartis Recent Developments/Updates Table 73. Daiichi Sankyo Corporation Information Table 74. Daiichi Sankyo Description and Business Overview Table 75. Daiichi Sankyo Multiple Myeloma Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 76. Daiichi Sankyo Multiple Myeloma Drugs Product Table 77. Daiichi Sankyo Recent Developments/Updates Table 78. Merck Corporation Information Table 79. Merck Description and Business Overview Table 80. Merck Multiple Myeloma Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 81. Merck Multiple Myeloma Drugs Product Table 82. Merck Recent Developments/Updates Table 83. AB Science Corporation Information Table 84. AB Science Description and Business Overview Table 85. AB Science Multiple Myeloma Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 86. AB Science Multiple Myeloma Drugs Product Table 87. AB Science Recent Developments/Updates Table 88. Teva Corporation Information Table 89. Teva Description and Business Overview Table 90. Teva Multiple Myeloma Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 91. Teva Multiple Myeloma Drugs Product Table 92. Teva Recent Developments/Updates Table 93. PharmaMar Corporation Information Table 94. PharmaMar Description and Business Overview Table 95. PharmaMar Multiple Myeloma Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 96. PharmaMar Multiple Myeloma Drugs Product Table 97. PharmaMar Recent Developments/Updates Table 98. Production Base and Market Concentration Rate of Raw Material Table 99. Key Suppliers of Raw Materials Table 100. Multiple Myeloma Drugs Distributors List Table 101. Multiple Myeloma Drugs Customers List Table 102. Multiple Myeloma Drugs Market Trends Table 103. Multiple Myeloma Drugs Growth Drivers Table 104. Multiple Myeloma Drugs Market Challenges Table 105. Multiple Myeloma Drugs Market Restraints Table 106. Global Multiple Myeloma Drugs Sales Forecast by Type (2022-2027) & (K Units) Table 107. Global Multiple Myeloma Drugs Sales Market Share Forecast by Type (2022-2027) Table 108. Global Multiple Myeloma Drugs Revenue Forecast by Type (2022-2027) & (US$ Million) Table 109. Global Multiple Myeloma Drugs Revenue Market Share Forecast by Type (2022-2027) Table 110. Global Multiple Myeloma Drugs Sales Forecast by Application (2022-2027) & (K Units) Table 111. Global Multiple Myeloma Drugs Sales Market Share Forecast by Application (2022-2027) Table 112. Global Multiple Myeloma Drugs Revenue Forecast by Application (2022-2027) & (US$ Million) Table 113. Global Multiple Myeloma Drugs Revenue Market Share Forecast by Application (2022-2027) Table 114. Global Multiple Myeloma Drugs Sales Forecast by Region (2022-2027) & (K Units) Table 115. Global Multiple Myeloma Drugs Sales Market Share Forecast by Region (2022-2027) Table 116. Global Multiple Myeloma Drugs Revenue Forecast by Region (2022-2027) & (US$ Million) Table 117. Global Multiple Myeloma Drugs Revenue Market Share Forecast by Region (2022-2027) Table 118. Research Programs/Design for This Report Table 119. Key Data Information from Secondary Sources Table 120. Key Data Information from Primary Sources List of Figures Figure 1. Product Picture of Multiple Myeloma Drugs Figure 2. Global Multiple Myeloma Drugs Market Share by Type in 2020 & 2027 Figure 3. Chemotherapy Product Picture Figure 4. Corticosteroids Product Picture Figure 5. Immunomodulators Product Picture Figure 6. Monoclonal Antibodies Product Picture Figure 7. Histone Deacetylase (HDAC) Inhibitors Product Picture Figure 8. Proteasome Inhibitors Product Picture Figure 9. Others Product Picture Figure 10. Global Multiple Myeloma Drugs Market Share by Application in 2020 & 2027 Figure 11. Men Figure 12. Women Figure 13. Global Multiple Myeloma Drugs Revenue, (US$ Million), 2016 VS 2021 VS 2027 Figure 14. Global Multiple Myeloma Drugs Market Size 2016-2027 (US$ Million) Figure 15. Global Multiple Myeloma Drugs Sales 2016-2027 (K Units) Figure 16. Global Multiple Myeloma Drugs Market Size Market Share by Region: 2016 VS 20210 VS 2027 Figure 17. Multiple Myeloma Drugs Sales Share by Manufacturers in 2020 Figure 18. Global Multiple Myeloma Drugs Revenue Share by Manufacturers in 2020 Figure 19. The Global 5 and 10 Largest Multiple Myeloma Drugs Players: Market Share by Revenue in 2020 Figure 20. Multiple Myeloma Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2021 Figure 21. Global Multiple Myeloma Drugs Sales Market Share by Region (2016-2021) Figure 22. Global Multiple Myeloma Drugs Sales Market Share by Region in 2020 Figure 23. Global Multiple Myeloma Drugs Revenue Market Share by Region (2016-2021) Figure 24. Global Multiple Myeloma Drugs Revenue Market Share by Region in 2020 Figure 25. U.S. Multiple Myeloma Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 26. Canada Multiple Myeloma Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 27. Germany Multiple Myeloma Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 28. France Multiple Myeloma Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 29. U.K. Multiple Myeloma Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 30. Italy Multiple Myeloma Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 31. Russia Multiple Myeloma Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 32. China Multiple Myeloma Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 33. Japan Multiple Myeloma Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 34. South Korea Multiple Myeloma Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 35. India Multiple Myeloma Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 36. Australia Multiple Myeloma Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 37. Taiwan Multiple Myeloma Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 38. Indonesia Multiple Myeloma Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 39. Thailand Multiple Myeloma Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 40. Malaysia Multiple Myeloma Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 41. Philippines Multiple Myeloma Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 42. Vietnam Multiple Myeloma Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 43. Mexico Multiple Myeloma Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 44. Brazil Multiple Myeloma Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 45. Argentina Multiple Myeloma Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 46. Turkey Multiple Myeloma Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 47. Saudi Arabia Multiple Myeloma Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 48. U.A.E Multiple Myeloma Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 49. Sales Market Share of Multiple Myeloma Drugs by Type (2016-2021) Figure 50. Sales Market Share of Multiple Myeloma Drugs by Application (2016-2021) Figure 51. Sales Market Share of Multiple Myeloma Drugs by Application in 2020 Figure 52. Revenue Share of Multiple Myeloma Drugs by Application (2016-2021) Figure 53. Revenue Share of Multiple Myeloma Drugs by Application in 2020 Figure 54. Manufacturing Cost Structure of Multiple Myeloma Drugs Figure 55. Manufacturing Process Analysis of Multiple Myeloma Drugs Figure 56. Multiple Myeloma Drugs Industrial Chain Analysis Figure 57. Channels of Distribution Figure 58. Distributors Profiles Figure 59. Bottom-up and Top-down Approaches for This Report Figure 60. Data Triangulation Figure 61. Key Executives Interviewed

Amgen Johnson & Johnson Celgene Takeda Pharmaceutical Novartis Daiichi Sankyo Merck AB Science Teva PharmaMar